DYN vs MAZE
DYN: Dyne Therapeutics is a clinical-stage biotechnology company developing targeted muscle therapeutics for rare diseases using its proprietary FORCE platform. MAZE: Maze Therapeutics leverages human genetics data and its Compass platform to discover and develop novel therapeutic candidates across multiple disease indications.
Side-by-side fundamentals
| Metric | DYN | MAZE | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $25.18 | $26.92 | |
| Market cap as of 2026-08-03 | $4.7B | $1.5B | |
| Net margin as of 2026-08-03 | n/a | +11.0% | |
| Operating margin as of 2026-08-03 | n/a | +34.4% | |
| ROE as of 2026-08-03 | -58.3% | -36.6% | MAZE higher |
| ROA as of 2026-08-03 | -46.8% | -31.8% | MAZE higher |
| Debt / equity as of 2026-08-03 | 0.18 | 0.11 | MAZE lower |
| Beta as of 2026-08-03 | 1.79 | 0.80 | |
| 1-year return as of 2026-07-31 close | +155.6% | +82.5% | DYN higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.